A Phase III, Randomized, Open-Label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment with or without Bevacizumab versus Standard of Care in Participants with Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-Line Platinum-Based Chemotherapy (TroFuse-021/ENGOT-ov85/GOG-3102)

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Shelly Seward, MD

Phase: III

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT07318558

Objective

This study will evaluate how long Sacituzumab Tirumotecan (sac TMT, MK 2870) used as maintenance treatment, with or without bevacizumab, compared with standard of care can help prevent cancer from growing or spreading in participants with newly diagnosed advanced non HRD positive ovarian cancer after first line platinum-based chemotherapy in the TroFuse 021, ENGOT ov85, and GOG 3102 trial. We will measure the time from the start of treatment until imaging shows that the tumor has grown or that new cancer spots appear.

Share:

Related Clinical Trials

Are Premature Infants with Bronchopulmonary Dysplasia Requiring Tracheostomy and Ventilation at Increased Risk of Atypical Craniosynostosis?
Randomized Trial Comparing Novel Fluoroscopy System with Conventional Fluoroscopy System in Fluoroscopy-Guided Endoscopic Procedures
A Phase I/II Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-Engaging Antibody that Targets STEAP2, CD3, and CD8 in Adult Participants with Metastatic Prostate Cancer (ACTIVATED-4-PC)
A Phase III Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors